Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

AGI Dermatics Dimericine

This article was originally published in Pharmaceutical Approvals Monthly

  • News

Executive Summary

Company plans to file a BLA in June for the T4N5 liposome lotion for prevention of basal cell carcinoma and actinic keratosis in patients with xeroderma pigmentosum. The BLA will be based on a 30-patient, one-year study reported March 24 in The Lancet. The annualized rate of new AK lesions was 8.2 for Dimericine vs. 25.9 for placebo, while the rate of new basal cell carcinoma lesions was 3.8 vs. 5.4. AGI plans to file an IND soon for evaluation of Dimericine in people without xeroderma pigmentosum who have had at least one AK or basal cell carcinoma lesio

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Joint Clinical Assessments: Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

US FDA's Califf Defends Agency Work On Marijuana Rescheduling, Animal Testing

See All
UsernamePublicRestriction

Register

PS001421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By